Behandlung der Acne fulminans mit Tumornekrosefaktor-α-Inhibitoren – eine Übersicht klinischer Fälle und der Literatur
Research output: Contribution to journal › Review › Research › peer-review
Standard
Behandlung der Acne fulminans mit Tumornekrosefaktor-α-Inhibitoren – eine Übersicht klinischer Fälle und der Literatur. / Taudorf, Elisabeth Hjardem; Jensen, Mikkel Bak; Bouazzi, Dorra; Sand, Carsten; Thomsen, Simon Francis; Jemec, Gregor Borut Ernst; Saunte, Ditte Marie Lindhardt.
In: JDDG - Journal of the German Society of Dermatology, Vol. 22, No. 1, 2024, p. 23-28.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Behandlung der Acne fulminans mit Tumornekrosefaktor-α-Inhibitoren – eine Übersicht klinischer Fälle und der Literatur
AU - Taudorf, Elisabeth Hjardem
AU - Jensen, Mikkel Bak
AU - Bouazzi, Dorra
AU - Sand, Carsten
AU - Thomsen, Simon Francis
AU - Jemec, Gregor Borut Ernst
AU - Saunte, Ditte Marie Lindhardt
PY - 2024
Y1 - 2024
N2 - Acne fulminans (AF) is a rare, serious, sudden-onset and long-lasting skin diseasethat causes scarring of face and body. Standard treatment with combined long-term isotretinoin and prednisolone is not always sufficient and has a well-knownpropensity for adverse effects leaving an unmet need for improved therapy. Casereports suggest that tumor necrosis factor (TNF)-αinhibitors may play a role inthe management of AF. In a 3-year retrospective data collection from two der-matology centers and literature review of clinical cases of acne fulminans treatedwith anti-TNF-αtherapy, three clinical cases and twelve literature cases were iden-tified. A total of five different TNF-αinhibitors have been tested, with adalimumabbeing the most commonly used. Clinical response was seen after 1 month in 2/3(67%) clinical cases and 5/12 (42%) literature cases, respectively, and treatmentwas successful in 2/3 (67%) and 11/12 (92%) after a median 3–7 months. All repor-ted adverse effects were mild and reversible. Anti-TNF-αtreatment may providerapid improvement in patients with AF when initial treatment with isotretinoinand prednisolone fails. However, randomized controlled trials are lacking, andexact dosage and timing need to be explored before clinical implementation.
AB - Acne fulminans (AF) is a rare, serious, sudden-onset and long-lasting skin diseasethat causes scarring of face and body. Standard treatment with combined long-term isotretinoin and prednisolone is not always sufficient and has a well-knownpropensity for adverse effects leaving an unmet need for improved therapy. Casereports suggest that tumor necrosis factor (TNF)-αinhibitors may play a role inthe management of AF. In a 3-year retrospective data collection from two der-matology centers and literature review of clinical cases of acne fulminans treatedwith anti-TNF-αtherapy, three clinical cases and twelve literature cases were iden-tified. A total of five different TNF-αinhibitors have been tested, with adalimumabbeing the most commonly used. Clinical response was seen after 1 month in 2/3(67%) clinical cases and 5/12 (42%) literature cases, respectively, and treatmentwas successful in 2/3 (67%) and 11/12 (92%) after a median 3–7 months. All repor-ted adverse effects were mild and reversible. Anti-TNF-αtreatment may providerapid improvement in patients with AF when initial treatment with isotretinoinand prednisolone fails. However, randomized controlled trials are lacking, andexact dosage and timing need to be explored before clinical implementation.
KW - Acne fulminans
KW - Adalimumab
KW - adalimumab
KW - anti-TNF-α therapy
KW - Anti-TNF-α-Therapie
KW - tumor necrosis factor-α inhibitors
KW - Tumornekrosefaktor-α-Inhibitoren
U2 - 10.1111/ddg.15234_g
DO - 10.1111/ddg.15234_g
M3 - Review
C2 - 38212919
AN - SCOPUS:85181945851
VL - 22
SP - 23
EP - 28
JO - JDDG - Journal of the German Society of Dermatology
JF - JDDG - Journal of the German Society of Dermatology
SN - 1610-0379
IS - 1
ER -
ID: 381070110